Christopher E Kline1, Martica H Hall2, Daniel J Buysse2, Conrad P Earnest3, Timothy S Church4. 1. 1 Department of Health and Physical Activity, Physical Activity and Weight Management Research Center, University of Pittsburgh , Pittsburgh, Pennsylvania. 2. 2 Department of Psychiatry, University of Pittsburgh , Pittsburgh, Pennsylvania. 3. 3 Department of Health and Kinesiology, Exercise and Sports Nutrition Laboratory, Texas A&M University , College Station, Texas. 4. 4 ACAP Health , Dallas, Texas.
Abstract
BACKGROUND: Poor sleep quality has previously been shown to be related to insulin resistance in apparently healthy adults. However, it is unclear whether an association between sleep quality and insulin resistance exists among adults with metabolic syndrome (MetS). METHODS: Participants included 347 overweight/obese postmenopausal women without type 2 diabetes (age: 57.5 ± 6.5 years; body mass index [BMI]: 31.7 ± 3.7 kg/m2; 54% with MetS). Sleep quality was assessed with the six-item Medical Outcomes Study Sleep Scale; values were categorized into quartiles. Insulin resistance was calculated from fasting glucose and insulin with the homeostasis model assessment of insulin resistance (HOMA2-IR) method. Analysis of covariance models were used to examine the association between sleep quality and HOMA2-IR after accounting for MetS and covariates (e.g., BMI, cardiorespiratory fitness, and energy intake). RESULTS: Women with the worst sleep quality had significantly higher HOMA2-IR values than women in all other quartiles (P ≤ 0.05 for each), and women with MetS had significantly higher HOMA2-IR values than women without MetS (P < 0.0001), but the relationship between sleep quality and HOMA2-IR did not differ between those with or without MetS (P = 0.26). Women with MetS in the worst quartile of sleep quality had higher HOMA2-IR values than all other women (P < 0.02). Taking >30 min to fall asleep, frequent restless sleep, and frequent daytime drowsiness were each related to higher HOMA2-IR values (each P < 0.04). CONCLUSIONS: Sleep quality is an important correlate of insulin resistance in postmenopausal women with and without MetS. Intervention studies are needed to determine whether improving sleep improves insulin resistance in populations at elevated cardiometabolic risk.
BACKGROUND: Poor sleep quality has previously been shown to be related to insulin resistance in apparently healthy adults. However, it is unclear whether an association between sleep quality and insulin resistance exists among adults with metabolic syndrome (MetS). METHODS:Participants included 347 overweight/obese postmenopausal women without type 2 diabetes (age: 57.5 ± 6.5 years; body mass index [BMI]: 31.7 ± 3.7 kg/m2; 54% with MetS). Sleep quality was assessed with the six-item Medical Outcomes Study Sleep Scale; values were categorized into quartiles. Insulin resistance was calculated from fasting glucose and insulin with the homeostasis model assessment of insulin resistance (HOMA2-IR) method. Analysis of covariance models were used to examine the association between sleep quality and HOMA2-IR after accounting for MetS and covariates (e.g., BMI, cardiorespiratory fitness, and energy intake). RESULTS:Women with the worst sleep quality had significantly higher HOMA2-IR values than women in all other quartiles (P ≤ 0.05 for each), and women with MetS had significantly higher HOMA2-IR values than women without MetS (P < 0.0001), but the relationship between sleep quality and HOMA2-IR did not differ between those with or without MetS (P = 0.26). Women with MetS in the worst quartile of sleep quality had higher HOMA2-IR values than all other women (P < 0.02). Taking >30 min to fall asleep, frequent restless sleep, and frequent daytime drowsiness were each related to higher HOMA2-IR values (each P < 0.04). CONCLUSIONS: Sleep quality is an important correlate of insulin resistance in postmenopausal women with and without MetS. Intervention studies are needed to determine whether improving sleep improves insulin resistance in populations at elevated cardiometabolic risk.
Authors: Isabel Ferreira; Colin A Boreham; Jos W R Twisk; Alison M Gallagher; Ian S Young; Liam J Murray; Coen D A Stehouwer Journal: J Hypertens Date: 2007-05 Impact factor: 4.844
Authors: Jacqueline M Lane; Jingjing Liang; Irma Vlasac; Simon G Anderson; David A Bechtold; Jack Bowden; Richard Emsley; Shubhroz Gill; Max A Little; Annemarie I Luik; Andrew Loudon; Frank A J L Scheer; Shaun M Purcell; Simon D Kyle; Deborah A Lawlor; Xiaofeng Zhu; Susan Redline; David W Ray; Martin K Rutter; Richa Saxena Journal: Nat Genet Date: 2016-12-19 Impact factor: 38.330
Authors: Lena L Law; Kate E Sprecher; Ryan J Dougherty; Dorothy F Edwards; Rebecca L Koscik; Catherine L Gallagher; Cynthia M Carlsson; Henrik Zetterberg; Kaj Blennow; Sanjay Asthana; Mark A Sager; Bruce P Hermann; Sterling C Johnson; Dane B Cook; Barbara B Bendlin; Ozioma C Okonkwo Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Miguel Meira E Cruz; Nenad Lukic; Aleksandra Wojczynska; Beat Steiger; Antonio Sérgio Guimarães; Dominik A Ettlin Journal: Front Neurol Date: 2019-05-28 Impact factor: 4.003
Authors: Anna Brzecka; Natalia Madetko; Vladimir N Nikolenko; Ghulam M Ashraf; Maria Ejma; Jerzy Leszek; Cyryl Daroszewski; Karolina Sarul; Liudmila M Mikhaleva; Siva G Somasundaram; Cecil E Kirkland; Sergey O Bachurin; Gjumrakch Aliev Journal: Curr Neuropharmacol Date: 2021 Impact factor: 7.363